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Summary  
Background: The therapeutic equivalence of generic and brand antiepileptic drugs, 
based on studies performed on healthy volunteers, has been questioned.  We compare, 
in a routine clinical setting, brand versus generic levetiracetam (LEV) bioequivalence 
in patients with epilepsy and also the clinical efficacy and tolerability of the 
substitution. 
Methods: A prospective, open-label, non-randomized, steady-state, multiple-dose, 
bioequivalence study was conducted in 12 patients with epilepsy (5 females), with a 
mean age of 38.4±16.2 years. Patients treated with the brand LEV (Keppra; UCB 
Pharma) were closely followed for a four-week period and subsequently switched to a 
generic LEV (Pharmaten) and followed for another four-week period. Blood samples 
were collected at the end of each 4-week period, during a dose interval for each 
formulation, for LEV concentration measurements by liquid chromatography mass 
spectrometry.  Steady-state area under the curve (AUC) and peak plasma 
concentration (Cmax) data were subjected to conventional average bioequivalence 
analysis. Secondary clinical outcomes, including seizure frequency and adverse 
events, were recorded. 
Results:  Patients had epilepsy for a mean period of 14.1±10.6 years and the mean 
daily LEV dose was 2583.3±763.7 mg.  The mean AUC±SD and Cmax±SD was 
288.4±86.3 (mg/L) h  and 37.8±10.4 mg/L respectively for brand LEV and 
319.2±104.7 (mg/L) h and 41.6±12.3 mg/L respectively for the generic LEV. Statistic 
analysis showed no statistical significant difference in bioequivalence. Also, no 
change in seizures frequency and/or adverse events was recorded.    
Conclusions: In our clinical setting, generic LEV was determined to be bioequivalent 
to brand LEV. Furthermore, seizures frequency or/and adverse events were not 
affected upon switching from brand to generic LEV. 
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Introduction   
Brand versus generic medications is a topic of debate and discussion, with 
most national governments encouraging the use of generic medicines and many 
healthcare systems supporting policies of substituting brand original drugs  with 
generic drugs, mainly for cost saving reasons1. This can be particularly important for 
patients with limited income and public insurance programs with constrained budgets.  
Since 1984, manufacturers rely on pharmaceutical equivalence and 
bioequivalence (BE) of generic products to the original brand name drug for approval 
by the Food and Drug Administration (FDA), since  it is not required to directly 
demonstrate the safety and efficacy of generic products in clinical trials2. Such studies 
generally evaluate the ratio of the generic product's area under the curve plasma 
concentration (AUC) versus the brand-name product's AUC and the ratio of the 
generic product's maximum concentration (Cmax) to the brand-name product's 
Cmax3,  in young healthy male volunteers. The FDA definition of bioequivalence 
requires that the 90% confidence intervals for the ratio of brand-to-generic AUC and 
Cmax fall within an acceptance interval of 0.80–1.25 (known as the “-20%/+25% 
rule”)4. Because of these approval requirements5, 6, generics are considered by some 
physicians and patients to be more problematic than brand-name medications. Indeed 
generic substitution has become an emotional issue among physicians and patients. 
 Of particular concern is whether patients prescribed generics may be at 
increased risk of therapeutic failure and/or side-effects7, 8, if small potential difference 
in BE variability occur9, 10, as with  AEDs with low bioavailability and solubility9 or 
with AEDs with a narrow therapeutic index10, 11.   Furthermore studies have shown 
switchback rates for AEDs are substantially higher than for non-AEDs10, 12. Loss of 
seizure control can have substantial medical, financial, and social consequences for 
patients with epilepsy, particularly those that are seizure-free on a particular branded 
AED.  
The issue of the interchangeability of brand and generic AEDs has increased 
recently because many clinically useful second generation AEDs have reached the 
end of their patent protection and various generic versions have been approved13.  
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In the present study, steady-state AUC and Cmax values were subjected to 
conventional average bioequivalence analysis (ABE) in patients with epilepsy, 
switched from brand levetiracetam (LEV) to generic LEV in a routine clinical practice 
setting. Secondary clinical outcomes, including seizure frequency and adverse events, 
were also recorded to determine the clinical efficacy and tolerability of the 
substitution. 
Methods 
Study design 
A prospective, open-label, non-randomized, steady-state, multiple-dose, 
bioequivalence study was conducted in patients with epilepsy, to compare brand 
(Keppra; UCB Pharma; Belgium) versus generic LEV (Pharmaten; Greece). The 
chosen generic is the most commonly prescribed LEV generic in Greece.  
Study population 
Subjects were adult patients treated with brand LEV for focal epilepsy. They 
were recruited from consecutive epilepsy patients attending the Outpatient Epilepsy 
Clinics at the University Hospital of Ioannina and at the Evagelismos Hospital, 
Athens, Greece, during 8 months (June 2014 to January 2015). To be eligible for the 
study, patients were being prescribed Keppra LEV during the previous 2 months and 
were to be switched to a generic, as part of their routine clinical treatment. Because 
the formulation switch was part of the routine clinical management of patients, and 
therefore considered to be a non-interventional study, it was not necessary to obtain 
specific ethical approval.  Instead, the Hospital Scientific Committee of both hospitals 
approved the study along with the patient consent protocol. The study protocol was in 
compliance with the Helsinki Declaration and informed consent was signed by all 
patients.  
Patients treated with the brand LEV were closely followed for a four-week 
period during which seizure frequency and adverse effects were recorded and 
subsequently  switched to  a generic LEV and followed for further  four-week period 
during which seizure frequency and adverse effects were again recorded. Blood 
samples were collected at the end of each 4-week period, during a dose interval for 
each formulation, for LEV concentration measurements by liquid 
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chromatography/mass spectrometry.  Blood samples were collected at 5 minutes prior 
to LEV ingestion and at 1, 2, 4, 8 and 12 hours post LEV ingestion. Plasma samples 
were stored frozen at -24 ° C until analyzed for LEV content. Steady-state AUC and 
Cmax data were subjected to conventional ABE analysis. Secondary clinical 
outcomes, including seizure frequency and adverse events, were recorded. 
Patients continued to take any concomitant AEDs and indeed drugs used to 
treat concomitant disorders. However, because adherence to their medications was 
essential, it was monitored by tablet counts and also by confirmation that LEV was 
ingested within 1 h of the scheduled dose time during the two previous days prior to 
pharmacokinetic sampling.  Because our patients were being evaluated in a routine 
clinical setting, patients were neither fasting nor advised as to restrict any aspect of 
the normal diet or lifestyle.  
LEV Analysis  
LEV concentration analysis was undertaken by liquid chromatography/mass 
spectroscopy (LC/MS) using a fully validated methodology in routine use within the 
Therapeutic Drug Monitoring Unit at the Chalfont Centre for Epilepsy. Validation 
was based on the most recent versions of the guidelines on bionalytical method 
validation of the European Medicines Agency and the US Food and Drug 
Administration (EMA, 2013; FDA 3-13)4, 5.   Briefly, an Agilent 1200 series 
automated LC with an Agilent 6400 series triple quad MS (Agilent Technologies, 
Stockport, Cheshire, UK) and a HiQ sil C18 column were used. Plasma (24 μL) were 
extracted with 500 μL acetonitrile and prepared for LC/MS analysis by use of a 
Gilson Quad-Z215 liquid handler (Gilson Instrumentation Services, Luton, 
Bedfordshire, UK). Calibration curve linearity was observed over the concentration 
range of 2-170 mg/L. The lower limit of quantification for LEV was 2.0 mg/L and the 
lowest limit of detection was 0.3 mg/L. The inter-assay and intra-assay coefficient of 
variation was 3.7-8.6% and 0.9-1.8% respectively. The measurement uncertainty for 
LEV was 5.8%.    
Statistical analysis and pharmacokinetics and bioequivalence analysis 
The continuous variables (e.g. age and weight) are presented as mean and 
standard deviation (SD), median, minimum and maximum values.  
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Shapiro-Wilk Normality Test was applied to the transformed AUC and Cmax 
differences between the brand and generic formulations; i.e. Ln(XGeneric) – Ln(XBrand). 
The bioequivalence of the two formulations was tested according to the following 
parameters: AUC- trapezoidal rule, as an index of extent of absorption, and Cmax, as 
an index of rate of absorption. For these parameters the following hypotheses were 
tested: H0: μGeneric/μBrand  0.80 or μGeneric/μBrand  1.25 (bioinequivalence) versus H1: 
0.80 < μGeneric/μBrand < 1.25 (bioequivalence) (α=0.05 for each direction, where 
μGeneric is the true (population) mean of the corresponding parameter for the Generic 
product and μBrand is the true (population) mean of the corresponding parameter for 
the Brand product (original measurements). 
 The point estimate for the ratio μGeneric/μBrand was computed by the formula: 
μGeneric/μBrand =exp(mean(Ln(XGeneric))-mean(Ln(XBrand))), while the 90% confidence 
interval (C.I.) for μGeneric/μBrand was computed using the following formula: C.I. = (eL, 
eU), where: L=(mean(Ln(XGeneric))-mean(Ln(XBrand)))-t(0.05, 14) √(2s2/N)        and           
U=(mean(Ln(XGeneric))-mean(Ln(XBrand)))+ t(0.05, 14). √(2s2/N). XBrand and XGeneric are 
the AUC or Cmax of brand and generic measurements respectively, s2 is the variance 
of the corresponding Ln-differences between brand and generic product, that is 
Ln(XGeneric) – Ln(XBrand), and t(0.05, 14) is the 5% upper percentile of T distribution 
with 14 degrees of freedom. If the corresponding C.I. was within the acceptance limits 
(0.80, 1.25) the bioequivalence of the two products – regarding the respective 
parameter - was accepted. (Note: (L,U) is a 90% C.I. for the mean difference between 
the Ln-transformed generic and brand data).  
 The Wilcoxon signed rank test was used to compare Tmax values for brand 
and generic formulations. The t-test was used to compare the Liverpool Adverse 
Event Profile scoring between brand and generic formulations. 
 
Outcome 
The primary pharmacokinetic outcome was the bioequivalence of two key 
pharmacokinetic parameters (AUC and Cmax), between the brand and the generic 
LEV formulations. The secondary pharmacokinetic outcome was Tmax.  
The secondary pharmacodynamic outcomes included changes in seizure 
frequency and/or adverse effects (AEs). Seizures were assessed from data captured 
Page 8 of 19 
 
daily, by each patient, in a paper diary. AEs were based on self-reporting, by use of 
the Liverpool Adverse Events Profile; each AE was  scored from 1-4, based on the 
absence (scored as 1) or the presence and the severity of AE (scored from 2-4)14. 
Results 
Study Population 
 
Twelve patients (5 females) were enrolled in the study during 8 months.  Their 
mean (± sd) age was 38.4±16.2 years and their mean (± sd) weight was 82.3±16.4 kg.  
Patients had epilepsy for a mean (± sd) period of 14.1±10.6 years and the 
mean (± sd) daily LEV dose was 2583.3±763.7 mg.  Patient characteristics are 
summarized in Table 1. 
 Pharmacokinetic Properties - Bioequivalence 
 The mean plasma LEV AUC±SD was 288.4±86.3 (mg/L) h for brand LEV 
and 319.2±104.7 (mg/L) h for the generic formulation. AUC, Cmax and Tmax values 
for each individual patient are shown in Table 2. Figure 1 shows the mean (±SD) LEV 
plasma concentration versus time curves for the brand and generic LEV formulations. 
The difference between the means of the Ln-transformed data – mean 
(Ln(XGeneric))-mean(Ln(XBrand)) - was 0.090  while the 90% C.I. for the same 
difference was (0.004, 0.175). Consequently, the point estimate of μGeneric/μBrand was 
1.094 and the 90% C.I. for the same ratio was (1.004, 1.191) which laid within the 
acceptance limits of bioequivalence . 
For Cmax, the mean±SD was 37.8±10.4 for brand LEV and 41.6±12.3 for the 
generic formulation. The difference between the means of the Ln-transformed data 
- mean(Ln(XGeneric))-mean(Ln(XBrand)) - was 0.085 while the 90% C.I. for the same 
difference was: (-0.006, 0.178). Consequently, the point estimate of μGeneric/μBrand was 
1.089 and the 90% C.I. for the same ratio is (0.993, 1.195) which laid within the 
acceptance limits for bioequivalence, with respect to Cmax . 
The mean±SD of Tmax was 1.3±0.4 h for the brand product and 1.1±0.3 h for 
the generic product. The median value was 1.0 for both products.  No statistically 
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significant difference was detected between the two LEV formulations (Wilcoxon 
signed rank test p-value =0.25). 
Efficacy and tolerability 
During the 4-week LEV brand ingestion the average seizure number was 1.2, 
whilst the average seizures number during the 4-week LEV generic ingestion was 1.3.  
Seven patients reported the same number of seizures during the brand and the generic 
LEV periods (five of these patients had no seizures when ingesting the brand LEV; 
and this was the case during the generic LEV).  Three patients had fewer seizures on 
the brand LEV (one of these patients had no seizures on the brand product and had 
one and two seizures on the generic product, accordingly), while two patients had less 
seizures on the generic product (one patient had one seizure on the brand product and 
no seizures on the generic product) (Table 3). 
The AEs, during brand and generic dosing, were similar. Using the Liverpool 
Adverse Effect Profile Scoring, a sum of scores for the presence and severity of AEs, 
was calculated for both groups. The mean±SD of the brand product score was 
33.6±14.2 while the score for the generic product was 33.8±10.2.  No statistically 
significant difference was observed between the two products: t-test p-value=0.95 
(Table 3). 
Discussion  
Generic AEDs are not considered to be inferior to branded AEDs as long as 
the same generic formulation is continued to be prescribed. Their unquestionable 
advantage is that they are substantially cheaper than the branded drug and this is of 
economic benefit to patients and health providers. However, there is substantial 
concern, often emotional, that generic drugs are not therapeutically equivalent to the 
branded versions. The concerns are that studies, typically single-dose studies in 
healthy male volunteers, do not represent the real-life setting in which generic 
substations would occur.    
The evidence that generic AED substitution may be problematic is primarily 
based on patient surveys15-18,  physician survey7, 18-20, studies of switch-back rates10, 12, 
21, studies of costs10, 22, 23 and specific association studies24. The ideal comparison of a 
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brand and generic AED would be that of a randomized control trial in patients with 
epilepsy and two such studies involving lamotrigine have recently been published25, 
26. Both these studies provide strong evidence that, at least for lamotrigine, concerns 
about generic substitution are largely misplaced. The study of Ting et al (2015)25 
compared steady-state lamotrigine plasma concentrations in 34 generic-brittle patients 
(i.e. patients with a confirmed history of having potential problems with generic 
switching) and observed that adverse effects were not related to the small (but 
allowable) pharmacokinetic differences that occur between brand and generic 
formulations. The study of Privitera et al (2016)26 comprised of 33 patients with 
epilepsy who underwent repeated switching between two lamotrigine generic 
products that were identified as having the lowest and highest bioavailability 
(compared to brand) sold in the USA. Not only were the two generic products 
determined to be bioequivalent but, in addition, there were no significant changes in 
seizure control or adverse effects.    
The present prospective, open-label, non-randomized, steady-state, multi-dose, 
bioequivalence study, reflective of every day clinical practice and conducted in 12 
patients with epilepsy, corroborate the studies of Ting et al (2015)25 and Privitera et al 
(2016)26 that concerns about generic substitution are largely misplaced. Our study 
population comprised both males and females and of various ages, various seizure 
frequency, on concomitant AEDs and various other non-AED drugs; characteristics 
typically encountered in a routine clinical setting. All patients underwent substitution 
of their branded LEV with that of a generic LEV formulation and based on 
bioequivalence criteria of AUC and Cmax values, the two formulations were 
considered to be bioequivalent (Figure 1).  Furthermore, substitution was not 
associated with any significant change in seizure frequency or adverse affects severity 
p=0.95).  
The physicochemical characteristics of a particular drug and whether or not it 
has a narrow therapeutic index would be expected to impact on bioequivalence and 
indeed there have been numerous such studies involving the older first generation 
AEDs - phenytoin, carbamazepine and valproic acid27-33.  In these studies, brand and 
generic carbamazepine30-33 and valproic acid34 were determined to be  bioequivalent  
whilst that of phenytoin, which has a narrow therapeutic index, was not27-29. For 
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carbamazepine, there was no significant difference in seizure frequency, nor in 
cognitive profile35, although Hartley et al (1991) observed more adverse events during 
the generic ingestion33.  
Because the new second generations AEDs have a more favorable 
pharmacokinetic profile than that of the older first generation36 they may be less prone 
to in-equivalence upon generic substitution and this is corroborated by our study. That 
a recent case report on 4 patients37 reported an increased incidence of seizures when 
treatment was switched from brand to generic LEV does not confirm in-equivalence 
because plasma LEV concentrations were not measured prior to or after the brand to 
generic switch was made, nor were LEV concentrations measured prior to or after the 
switchback.  
The limitations of this study are that although no significant difference in 
seizures frequency or adverse effects was observed, the sample size and baseline 
seizure frequency were not sufficiently powered to detect differences. Also, it is not 
known how many of the patients investigated were generic-brittle patients who might 
be particularly susceptible to experiencing adverse effects consequent to a formulation 
change. A further limitation is that the study design was open and non-randomised in 
design.  
 
Conclusion 
Patients and physicians have concerns that generic AEDs may not be 
bioequivalent to that of brand formulations and consequently generic drug substitution 
may cause therapeutic failure or increased risk of adverse effects. The present study of 
12 patients with epilepsy, with characteristics typically encountered in a routine 
clinical setting, entailed substitution of their branded LEV with that of a generic LEV 
formulation and based on bioequivalence criteria the two formulations were 
concluded to be bioequivalent. Whether these data can be extrapolated to other AEDs 
is not known. However, as a rule of thumb when a planned generic substitution is to 
occur, it is important to measure blood concentrations before and after substitution so 
that if seizure breakthrough occurs or adverse effect presents, the contribution of in-
equivalence can be more readily ascertained38.  
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Figure Legend 
Figure 1: Mean (±SD) levetiracetam (LEV) plasma concentration versus time curves for 
brand (n=12) and generic (n = 12)LEV formulations 
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Table 1: Patient characteristics   
 
 
AEDs = antiepileptic drugs; LEV = levetiracetam 
 
 
 
 
 
 
Patient Gender 
Age 
(years) 
Weight 
(kg) 
LEV dose/day 
(mg) 
Epilepsy  
duration 
 (years) 
Concomitant 
 AEDs  
Concomitant  
non-AEDs 
1 Male 21 80.5 4000 5 
Topiramate 
    Lacosamide 
0 
2 Male 39 85 3000 20 
Clonazepam 
 Citalopram 
Oxcarbazepine 
0 
3 Male 47 97 3000 31 
Carbamazepine 
Pregabalin 
0 
4 Male 29 98 3000 9 
Carbamazepine 
Phenobarbital 
Topiramate 
0 
5 Female 29 63 1000 17 0 Ferrous sulphate 
6 Male 22 77 3000 5 
Lacosamide 
Oxcarbazepine  
0 
7 Female 48 53 2000 15 0 0 
8 Female 37 80 2000 10 0 0 
9 Male 79 70 2500 1 0 
Aloperidin 
Omeprazole 
10 Female 27 75 2500 15 
 Zonisamide 
 
Ferrous sulphate 
         11 Male 32 105 3000 30 
         
Oxcarbazepine 
Zonisamide 
 
Bromazepam   
Ramipril 
12 Female 51 105 2000 25 
 Clobazam 
Lacosamide 
Valproic acid 
 
 Thyrormone 
Mean  
 
 38 82        2583 14                -                        - 
Median      34      80 2750 12                -                        - 
SD  16 16 764           11 -                        - 
Minimum  21 53 1000 1 0 0 
Maximum  79 105 4000 31 3 2 
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Table 2: Pharmacokinetic parameters for brand and generic levetiracetam 
formulations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Patients 
Brand Generic 
AUC 
(mg/L)h 
Cmax 
(mg/L) 
Tmax(h) AUC 
(mg/L)h  
Cmax, 
(mg/L) 
Tmax (h) 
1 377.0 45.0 2.0 423.2 55.0 1.0 
2 263.7 32.0 2.0 294.2 47.0 1.0 
3 276.0    30.0      1.0 300.5 33.0 1.0 
4 261.0 43.0 1.0 370.0 42.0 1.0 
5 147.2 20.0 1.0 124.4 16.0 1.0 
6 196.0 33.0 1.0 234.6 41.0 1.0 
7 398.7 56.0 1.0 427.9 62.0 1.0 
8 297.5 43.0 1.0 293.4 40.0 1.0 
9 435.0 46.0 2.0 526.6 55.0 2.0 
10 195.0 24.0 1.0 276.0 32.0 1.0 
11 327.8 45.0 1.0 299.4 40.0 1.0 
12 286.2 36.0 2.0 260.5 36.0 1.0 
Mean 288.4 37.8 1.3 319.2 41.6 1.1 
Median 281.1 39.5 1.0 296.8 40.5 1.0 
SD 86.3 10.4 0.5     104.7 12.3 0.4 
Minimum 147.2 20.0 1.0    124.4 16.0 1.0 
Maximum 435.0 56.0 2.0 526.6 62.0 2.0 
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Table 3: Seizures number and Liverpool Adverse Effect Profile (LAEP) for brand and 
generic levetiracetam formulations  
Patient Seizures number*       
Brand 
Seizures number* 
Generic 
LAEP Score 
               Brand 
LAEP Score 
Generic 
1 4 1 19 19 
2 0 0 38 39 
3 0 2 26 23 
4 0 0 32 44 
5 0 0 23 39 
6 2 4 22 23 
7 0 0 33 39 
8 0 0 70 52 
9 1 0 30 30 
10 2 3 51 40 
11 2 2 28 34 
12 4 4 31 23 
Mean 1.2 1.3 33.6 33.8 
Median 0.5                0.5 30.5 36.5 
SD 1.5 1.6 14.2 10.2 
Minimum 0 0 19 19 
Maximum 4 4 70 52 
* Number of seizures during a four week period 
 
